Missing Avatar

Evelin Szakal

Director of Business Development - Next Interactions

I am a business and science professional, dealing with business development, client relations, finances and marketing at Next Interactions. Previously I was co-founder and director of corporate development at a biotech startup, TheraBiol, Inc. in San Francisco. I bring extensive experience in program-, project- and quality management in clinical and non-clinical biotech research from TBI, UCSF and Vaccine Research Center, a CRO in Finland carrying out clinical studies for major pharmaceuticals. I hold a BS in economics, a Ph.D. in medical microbiology and completed my postdoc at UCSF studying protein complexes.

Position - Company  
Director of Business Development - Next Interactions Sep 2016 - Present
  • Evelin Szakal hasn't added any educational information yet...

Publication Info
Generalized schemes for high-throughput manipulation of the Desulfovibrio vulgaris genome. Chhabra SR, Butland G, Elias DA, Chandonia JM, Fok OY, Juba TR, Gorur A and 21 others Appl Environ Microbiol. 77(21):7595-604. doi: 10.1128/AEM.05495-11. September 9, 2011. View on PubMed.
Norovirus GII-4 causes a more severe gastroenteritis than other noroviruses in young children. Huhti L, Szakal ED, Puustinen L, Salminen M, Huhtala H, Valve O, Blazevic V, Vesikari T J Infect Dis. 203(10):1442-4. doi: 10.1093/infdis/jir039. May 15, 2011. View on PubMed.
Norovirus genotypes in endemic acute gastroenteritis of infants and children in Finland between 1994 and 2007. Puustinen L, Blazevic V, Huhti L, Szakal ED, Halkosalo A, Salminen M, Vesikari T Epidemiol Infect. 140(2):268-75. doi: 10.1017/S0950268811000549. April 14, 2011. View on PubMed.
Norovirus gastroenteritis in young children receiving human rotavirus vaccine. Zeng SQ, Halkosalo A, Salminen M, Szakal ED, Karvonen A, Vesikari T Scand J Infect Dis. 42(6-7):540-4. doi: 10.3109/00365541003652556. July 2010. View on PubMed.
One-step quantitative RT-PCR for the detection of rotavirus in acute gastroenteritis. Zeng SQ, Halkosalo A, Salminen M, Szakal ED, Puustinen L, Vesikari T J Virol Methods. 153(2):238-40. doi: 10.1016/j.jviromet.2008.08.004. September 17, 2008. View on PubMed.
A short report on highlights of world-wide development of RIX4414: an European experience. Vesikari T, Karvonen A, Puustinen L, Szakal ED, Zeng SQ, Delem A, De Vos B Vaccine. 24(18):3779. doi: 10.1016/j.vaccine.2005.07.028. May 1, 2006. View on PubMed.
Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Vesikari T, Karvonen A, Puustinen L, Zeng SQ, Szakal ED, Delem A, De Vos B Pediatr Infect Dis J. 23(10):937-43. October 2004. View on PubMed.
Comparison of media for the selective culture of enteroinvasive Escherichia coli. Szakál D, Pál T Eur J Clin Microbiol Infect Dis. 22(4):235-41. doi: 10.1007/s10096-003-0908-4. April 2003. View on PubMed.
A colony blot immune assay to identify enteroinvasive Escherichia coli and Shigella in stool samples. Szakál D D, Schneider G, Pál T Diagn Microbiol Infect Dis. 45(3):165-71. March 2003. View on PubMed.
A colony blot immunoassay to detect enteroinvasive Escherichia coli and Shigella in water samples. Szakál D, Gadó I, Pál T J Appl Microbiol. 90(2):229-36. February 2001. View on PubMed.
  • Evelin Szakal hasn't received any ratings yet...